Statements Data availability statement The RNA-seq data was submitted to the NCBI (SRA) database with ID: PRJNA1193114
According to a clinical study, semaglutide shows noticeable weight loss after 4 weeks
Journal of the American Pharmacists Association: JAPhA, 64 (1), 133138
Individuals with a personal or family history of Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or an allergy to Semaglutide should not use this injection
References The DREAMS-3 Phase III clinical study of Masdutide, a head-to-head semaglutide trial, achieved its primary endpoint in dual efficacy in reducing blood sugar and weight, 28 Oct 2025, Innovent Biologics, A Study Comparing IBI362 vs Semaglutide in Chinese Adults with Early Type 2 Diabetes and Obesity, ClinicalTrials.gov ID NCT06184568, Ji L, et al, Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial